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Introduction
Recent advances in diagnostic imaging modalities (spiral CT; PET 
or CT-PET) and improved survival due to multimodality treatment, 
have increased the rate of clinical detection of a second focus of lung 
cancer in the lungs. The presentation may be metachronous. In these 
patients, the tumours are separated in time. Patients may also be seen 
with synchronous tumours either within the same lobe, the same lung 
or the contralateral lung. Differentiating synchronous primary lung 
cancer from intrapulmonary metastasis or differentiating metachronous 
primary lung cancer from recurrent lung cancer can be difﬁcult when 
the tumour histology is the same. According to the guidelines proposed 
by Martini and Melamed (1), tumours with the same histology might be 
considered synchronous if they are found in a different segment, lobe 
or lung; there is no carcinoma in lymphatics common to both; and there 
is no evidence of extrapulmonary metastasis at the time of diagnosis. 
Tumours with the same histology might be considered metachronous 
if there has been a disease free survival of at least two years or second 
tumour is found in a different segment, lobe or lung; there is no car-
cinoma in the lymphatics common to both, and there is no evidence 
of extrapulmonary metastasis at the time of diagnosis. Although these 
deﬁnitions are far from perfect, they still provide the most useful and 
most frequently used criteria for the deﬁnition of second primary lung 
cancers. Molecular biology may be the best method for distinguishing 
recurrence-metastasis from second primary cancer. However, at the 
moment these techniques are of no value in the pre-resection analysis 
of tumour cytology.
Synchronous primary lung cancers
Approximately 1/3 of multiple primary lung cancers present as syn-
chronous cancer. A special subgroup are patients with a satellite lesion. 
In these patients, a synchronous second tumour of identical histology 
to the main tumour is found in the same lobe. The occurrence of such 
satellite nodules is surprisingly common, being found in approximately 
7% of patients who have undergone resection. The overall 5-year 
survival for patients with satellite nodules in the same lobe is relatively 
good (35%). When the nodes are negative, survival is even approxi-
mately 60% (2). This relatively good survival of patients with satellite 
nodules compared to patients with synchronous lung cancer in another 
lobe suggests that a local mechanism of spread is occurring. Satellite 
nodules are usually found in patients with adenocarcinoma.
In contrast with survival of patients with satellite nodules, the 5-year 
survival of patients with synchronous primary lung cancer has been 
disappointingly low. In the study by Deschamps et al. the 5-year sur-
vival was 16% (3). In a retrospective study of the Leuven Lung Cancer 
group survival 5-year survival was 33% (4). Survival of patients with 
synchronous primary lung cancer has consistently been reported to be 
lower compared to survival of metachronous primary lung cancer. It 
is quite likely that many patients with synchronous focus of cancer of 
the same histologic type have actually a metastasis. However, it is not 
possible to discriminate this before resection has been performed. We 
should be cautious to accept the diagnosis based on cytology alone 
because the accuracy of determining cell type by biopsies or cytologi-
cal studies is only 60 to 80% (5).
In patients with the diagnosis of synchronous second primary lung 
cancer in another lobe, careful staging for distant metastasis and/or 
locoregional lymph node metastasis should be carried out because 
survival of patients with synchronous primary lung cancer is poor, even 
when the 2 lesions are of different histological type. In these patients 
we recommend to perform always imaging of the brain (CT/MRI) and 
mediastinoscopy. Patients with adequate pulmonary and physiologic 
reserve should undergo surgical resection of the second lesions after 
careful staging. In general, limited resection is performed for second 
peripheral cancer. However, if the patient can tolerate another lobec-
tomy, this should be the procedure of choice. When at thoracotomy, 
2 malignant lesions are found, the largest lesion is best treated by an 
anatomical resection. For the smaller lesion, a lesser resection (wedge 
or segmentectomy) is acceptable. In this setting, pneumonectomy 
(especially on the right side) should be avoided because of the higher 
mortality and morbidity, the poorer tolerance to adjuvant chemotherapy 
and the poor long-term survival. There are no data, but it seems logical 
that patients with resected synchronous lung lesions may beneﬁt from 
adjuvant chemotherapy.
Metachronous multiple primary lung cancer
The incidence of subsequent lung cancer after resection has been 
estimated to be 1% to 4% per patient/year. On average 5 year after re-
section, a lung cancer patient has a 10% risk of developing a new lung 
cancer. The histology of the metachronous second primary lung cancer 
is the same as that of the ﬁrst lung cancer in 2/3 of the patients. Studies 
show that the incidence of new primary lung cancer is much higher 
in patients who originally had a central tumour and in patients with 
squamous cell carcinoma. Approximately 2/3 of patients with second 
primary lung cancer can undergo resection. In about 1/3 of the patients, 
the resection will be performed by a limited resection (wedge exci-
sion or segmentectomy). Pulmonary resection for second primary after 
pneumonectomy is feasible (6). Absolute contraindications for resec-
tion after pneumonectomy are an anatomic location requiring lobec-
tomy or more for complete resection, an inadequate pulmonary reserve 
tolerate resection and pulmonary hypertension. Even if pulmonary 
function seems to tolerate lobectomy, it is unlikely that most patients 
will survive or have an adequate quality of life with a single remaining 
lobe because of the limited pulmonary vascular bed. 
The survival rate after resection of a metachronous tumours is better 
compared to survival after resection of a synchronous tumours but is 
lower compared to survival after resection of a ﬁrst primary tumour. 
Even for patients with resected metachronous stage I tumours, a 5-year 
survival of less than 50% has consistently been reported (3, 7-8). The 
survival rate of patients with tumours of the same histologic type has 
been found to be not different to that of patients with tumours of differ-
ent histologic types. In most studies, the disease free interval between 
the ﬁrst and second primary tumours predicts survival. 
Rice and colleagues examined the risk of second primary tumour after 
resection of stage I non-small cell lung cancer. Eighty-two percent of 
patients were asymptomatic at the time of second primary lung cancer 
diagnosis and showed abnormal ﬁndings on the follow-up chest X-ray. 
Sixty-three per cent of patients underwent surgical resection of their 
second primary lung cancer. After surgery for second primary lung 
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cancer, the median survival was 4,1 years. The potential to improve 
survival coupled with the fact that most second primary lung cancers 
are asymptomatic at the time of diagnosis suggest that careful post-
operative surveillance of patients with early stage non-small cell lung 
cancer is warranted. 
In patients with synchronous cancers located in different lungs, a staged 
bilateral thoracotomy at an interval of 4 to 6 weeks is recommended. 
It seems logical to start at the side with the higher stage of the disease. 
When a complete resection was performed, the contralateral side can be 
explored and eventually resected. 
Conclusion
The management of patients in whom a second primary lung cancer 
develops remains a challenging problem. However, there appears to be 
a beneﬁt from surgical resection in well selected patients. 
Prognosis after resection of a synchronous tumour is substantially 
lower compared to prognosis after resection of a metachronous lesion. 
An exception are satellite nodules in the same lobe which have a better 
prognosis after resection.
Because accurate differentiation of synchronous or metachronous 
tumours from intrapulmonary metastasis or recurrent lung cancer is not 
always clinically possible, patients with adequate pulmonary and physi-
ologic reserve should undergo surgical resection of the second lesions 
after careful staging. 
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Owing to the advent of reﬁned chest CT images with higher resolution 
and CT screening programs, smaller lung cancers are being discovered 
in asymptomatic patients. Most of them are more often found on a 
low-dose CT images, and they tend to have characteristic appearance 
on high-resolution CT scan as ground glass opacity (GGO), a focal 
intermediate/mild increase in the CT density. Of course, the screening 
program is still picking up the more solid tumors with/without lymph 
node involvement, the percentage of GGO or GGO-like lesions is 
obviously increased in low-dose CT screening era. These GGO tumors 
are pathologically characterized by the morphology of non-/minimally 
invasive form of well-differentiated adenocarcinoma termed as bron-
chioloalveolar carcinoma (BAC) of the non-mucinous type. 
The superb prognosis of these GGO-BAC tumors is being recognized 
in the surgical community. Although the gold standard operation for 
peripheral lung cancer has been lobectomy with lymph node sampling/
dissection, the revision is thought to be necessary, especially for these 
screen-detected GGO-BAC tumors. The possibility of limited resection 
such as segmentectomy/wedge resection seems to be realistic. Enough 
number of institutional reports describing the equivalent surgical 
outcome by limited resection have been accumulated. Therefore, the 
randomized phase III trial between lobectomy and limited resection is 
being planned both in US and Japan in a non-inferiority design setting. 
The results of these studies might be applied in the management of 
screen-detected, small-sized tumors in the near future.
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Approximately 40,000 patients / year are diagnosed with Stage III 
NSCLC. The cure rate with surgery or radiation therapy alone is less 
than 10%. There is signiﬁcant local failure with bimodality treatment. 
Treatments include concurrent chemoradiation or chemotherapy fol-
lowed by surgery. Trimodality therapy is both attractive and feasible. 
We have results from several trials available including SWOG 8805 
(stage IIIA & IIIB), INT 0160 (Pancoast ) and radiation therapy limited 
to 45 Gy. 
Current protocols studying the importance of mediastinal lymph node 
clearance are SWOG 8805; Brigham & Womens (Bueno et al., 2000); 
and CALGB 8935. The importance of pathologic complete response 
was studied by INT 0139. The University of Maryland study found 
high-dose radiation treatments to be attractive and feasible.
Residual disease is frequently present after chemoradiotherapy. This 
viable tumor may be the only disease present and resection may lead to 
cure. The incidence of local recurrence is signiﬁcant. Actual experience 
conﬁrms these assumptions. Dillman et al., in CALGB #8433î found 
median survival improved with chemotherapy. Using radiation therapy 
alone median survival was 9.7 months. Chemotherapy and radiation re-
sulted in median survival of 13.8 months. With OS improved at 7 years, 
6% with radiation alone and 13% with chemotherapy and radiation. 
(Furuse et al. J Clin Oncol 17:2692-99, 1999).
Trimodality was studied using PE x 2 cycles with XRT (45Gy) Fol-
lowed by Surgical resection in 126 Pathologic IIIa (N2) =60%, and 
pathologic IIIb = 40%. 3 year survival for IIIa = 27% and IIIb was 
24%. 5 year survival was 23% vs 21%. Pathologic complete response 
was 21% and microscopic foci were present only in 37%. A major 
path response was seen in 58%. Patients with lymph node involvement 
showed an improved survival. Grade 4 toxicity was evident in13%; 
Mortality rate was 6%. The brain was the major site of relapse in 40%; 
the sole site in 10%. INT0139 was a phase III Comparison of Chemo-
radiotherapy vs Chemoradiotherapy followed by Surgery in IIIa (N2) 
